• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Propel Software Accelerates Adoption of Agentic AI for PLM, QMS & PIM with Early Customers Using Live Data

    10/9/25 9:04:00 AM ET
    $ALGM
    $GH
    Semiconductors
    Technology
    Medical Specialities
    Health Care
    Get the next $ALGM alert in real time by email

    Technology, Medical Device, and Consumer Goods Companies Achieve Business Efficiencies with Propel One Agentic AI Solution

    Propel, creator of the first product value management (PVM) platform to transform how businesses create, sell, and service products, announces Propel One first customer cohort. Combining the power of Propel's unified, intelligent product thread with the security and scalability of Salesforce Agentforce, Propel One's agentic AI enables users to leverage trusted, relevant product data every time for secure, highly-reliable outcomes. Propel will be on site at Dreamforce 2025 to meet with manufacturing clients across high technology, medical device, industrial, and consumer goods industries and discuss its latest technology including Propel One.

    Propel One introduces agentic AI workflows that go beyond simple automation. By combining Propel's intelligent product thread with Salesforce Agentforce, every AI action is governed by enterprise-grade protections, role-based permissions, and context-aware relationships that eliminate hallucinations and ensure precise, business-relevant outcomes. The platform incorporates trusted product data models including items, bill of materials (BOMs), changes, documents, and metadata, with a robust security layer, and advanced role-based permissions to safeguard sensitive information across every record, document, or field.

    "AI is transforming the way product manufacturers operate, and Propel is at the forefront of this evolution, delivering innovative, agentic solutions that support every stage of the product lifecycle. It's AI that doesn't just automate, but anticipates and acts," said Ross Meyercord, CEO of Propel Software. "Propel One was built to streamline workflows and enhance efficiency in product operations. Early use cases are generating excitement as AI flags component replacements from real-time quality and supply chain data, automatically notifying engineers with recommended solutions, triggering change orders, and streamlining approvals across the organization."

    With many customers representing the company's target industries, sample Propel One early adopters and evaluation partners include Allegro MicroSystems (NASDAQ:ALGM), a global leader in power and sensing solutions for motion control and energy-efficient systems; Breg, Inc, a provider of orthopedic bracing and support solutions; and Guardant Health (NASDAQ:GH), a precision oncology company specializing in developing blood-based liquid biopsy cancer tests.

    "At Guardant, we are utilizing Propel One to determine how we can empower employees at every role and skill level within our organization to make smarter decisions, faster," said Matt Pearson, Vice President, Quality System & Risk, Guardant. "With all of our product information available digitally on a single platform we are confident that Propel One is leveraging accurate, data-driven intelligence to optimize responses that will make our business more efficient - a critical success factor for our company."

    Propel One enables users to analyze, monitor, and accelerate processes across the product lifecycle to increase productivity for PLM and QMS-related workflows, including:

    • Product Management: boost product intelligence with AI workflows for item summaries, attachment inquiries, and bulk item creation
    • Change Management/Corrective Action Preventive Action (CAPA)/ Non-Conformance (NCR): speed decision making with AI-powered summaries, attachment inquiries, and assignments for missing or required information
    • Design for Serviceability: analytics connect field cases to product lines for data-driven engineering improvements; deliver answers faster in AI-powered product service documents
    • Document Management: agentic AI streamlines document summaries, inquiries, and description generation
    • Training Management: boost compliance and affirm due diligence with AI-generated quizzes for shop floor, field techs, or service providers

    "The Propel One early adopter program is demonstrating how we can accelerate engineering change order processing," said Jeannie Villalobos, Senior Manager, Quality Systems, Breg. "Streamlining change processes while maintaining proper control and oversight will enable our engineers to focus on more strategic, innovative tasks. We are excited to be working hand-in-hand with Propel to uncover efficiency gains across our organization with its new agentic AI solution."

    If you are attending Dreamforce and would like to learn more about the Propel One solution, click here.

    About Propel Software

    Propel helps product companies grow revenue and increase business value. Our product value management platform connects commercial and product teams to optimize decision making, drive process efficiencies, and engage customers with compelling products and experiences. Propel has a proven track record of improving product quality, speeding time to revenue and profit, and improving customer satisfaction. Recognized as one of America's fastest growing private companies on the Inc. 5000, Propel is a 4x Deloitte Technology Fast 500 winner, and one of Fortune America's Most Innovative Companies. Built on Salesforce, Propel drives product success for hyper growth startups, corporate pioneers, and Fortune 500 leaders in the high tech, medtech and consumer goods industries. For more information, visit propelsoftware.com and follow us on LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251009758567/en/

    Media Contact:

    Jessica Mularczyk, [email protected]

    Get the next $ALGM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGM
    $GH

    CompanyDatePrice TargetRatingAnalyst
    Guardant Health Inc.
    $GH
    9/25/2025$75.00Peer Perform → Outperform
    Wolfe Research
    Guardant Health Inc.
    $GH
    9/22/2025$72.00Overweight
    Wells Fargo
    Allegro MicroSystems Inc.
    $ALGM
    8/1/2025$42.00 → $37.00Buy
    TD Cowen
    Allegro MicroSystems Inc.
    $ALGM
    6/16/2025$38.00Buy
    BofA Securities
    Guardant Health Inc.
    $GH
    4/10/2025$55.00Outperform
    Mizuho
    Guardant Health Inc.
    $GH
    1/23/2025$60.00Overweight
    Barclays
    Allegro MicroSystems Inc.
    $ALGM
    11/22/2024$23.00Overweight
    Wells Fargo
    Allegro MicroSystems Inc.
    $ALGM
    11/12/2024$30.00Buy
    Loop Capital
    More analyst ratings

    $ALGM
    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Krognes Steve E. converted options into 154 shares, increasing direct ownership by 0.84% to 18,436 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    11/3/25 5:45:36 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Mignone Roberto converted options into 3,167 shares (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    10/22/25 7:07:55 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 21% to 1,315 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    10/20/25 7:50:40 PM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Guardant Health to Participate in Upcoming Investor Conferences

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 19 at 9:30 a.m. Greenwich Mean Time Piper Sandler 37th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 2 at 8:30 a.m. Eastern Time Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every

    11/7/25 8:00:00 AM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on October 21, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 184,961 shares of its common stock to 272 new non-executive employees and one non-qualified stock option award to purchase 5,731 shares of its common stock to one new non-executive employee with a grant date of October 31, 2025 under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"). The RSUs and stock options were granted as inducements material to the employees entering into employment with Guardant i

    11/6/25 6:35:00 PM ET
    $GH
    Medical Specialities
    Health Care

    New Study Validates Guardant Reveal Blood Test's Effectiveness in Monitoring Chemotherapy Response

    Tissue-free Guardant Reveal test identifies disease progression up to 18 months earlier than standard clinical measures in patients with advanced cancer Longitudinal circulating tumor DNA (ctDNA) monitoring across multiple timepoints provides a more accurate prediction of treatment response and disease progression than a single on-treatment analysis, reinforcing the clinical value of serial testing Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced new data demonstrating that its Guardant Reveal® blood test helps clinicians to assess the effectiveness of chemotherapy in patients with advanced solid tumors months earlier than conventional methods. T

    11/6/25 8:05:00 AM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    SEC Filings

    View All

    Guardant Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - Guardant Health, Inc. (0001576280) (Filer)

    11/7/25 5:17:52 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 424B5 filed by Guardant Health Inc.

    424B5 - Guardant Health, Inc. (0001576280) (Filer)

    11/6/25 4:34:10 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form FWP filed by Guardant Health Inc.

    FWP - Guardant Health, Inc. (0001576280) (Subject)

    11/5/25 8:42:28 AM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guardant Health upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Guardant Health from Peer Perform to Outperform and set a new price target of $75.00

    9/25/25 8:22:52 AM ET
    $GH
    Medical Specialities
    Health Care

    Wells Fargo resumed coverage on Guardant Health with a new price target

    Wells Fargo resumed coverage of Guardant Health with a rating of Overweight and set a new price target of $72.00

    9/22/25 8:30:36 AM ET
    $GH
    Medical Specialities
    Health Care

    TD Cowen reiterated coverage on Allegro Microsystems with a new price target

    TD Cowen reiterated coverage of Allegro Microsystems with a rating of Buy and set a new price target of $37.00 from $42.00 previously

    8/1/25 8:20:32 AM ET
    $ALGM
    Semiconductors
    Technology

    $ALGM
    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CTO Doogue Michael covered exercise/tax liability with 2,319 shares and bought $285,000 worth of shares (15,000 units at $19.00), decreasing direct ownership by 4% to 62,404 units (SEC Form 4)

    4 - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Issuer)

    11/19/24 4:16:05 PM ET
    $ALGM
    Semiconductors
    Technology

    President and CEO Nargolwala Vineet A bought $99,446 worth of shares (5,000 units at $19.89), increasing direct ownership by 1% to 356,113 units (SEC Form 4)

    4 - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Issuer)

    11/6/24 4:16:05 PM ET
    $ALGM
    Semiconductors
    Technology

    Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    3/19/24 5:29:06 PM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Guardant Health Inc.

    SC 13G - Guardant Health, Inc. (0001576280) (Subject)

    11/13/24 7:34:17 PM ET
    $GH
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allegro MicroSystems Inc.

    SC 13G/A - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Subject)

    11/12/24 1:21:32 PM ET
    $ALGM
    Semiconductors
    Technology

    Amendment: SEC Form SC 13G/A filed by Allegro MicroSystems Inc.

    SC 13G/A - ALLEGRO MICROSYSTEMS, INC. (0000866291) (Subject)

    11/12/24 9:50:12 AM ET
    $ALGM
    Semiconductors
    Technology

    $ALGM
    $GH
    Financials

    Live finance-specific insights

    View All

    Allegro MicroSystems Reports Second Quarter 2026 Results

    MANCHESTER, N.H., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. ("Allegro" or the "Company") (NASDAQ:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its second quarter ended September 26, 2025. "We delivered strong second quarter results, with sales of $214 million, up 14% year-over-year, and led by growth in both e-Mobility and Industrial & Other, increasing 21% and 23% year-over-year, respectively. Non-GAAP EPS was $0.13, increasing more than 60% year-over-year," said Mike Doogue, President and CEO of Allegro. "We saw broad strength in second quarter Automotive sales

    10/30/25 7:00:00 AM ET
    $ALGM
    Semiconductors
    Technology

    Guardant Health Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

    Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data Raises 2025 revenue guidance to $965 to $970 million, representing year-over-year growth of 31% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights For the three-month period ended September 30, 2025, as compared to the same period of 2024: Reported total revenue of $265.2 million, an increase of 39%, driven by: Oncology revenue of $184.4 million, an increase of 31%, and approximately 74,000 oncology tests, an increase of 40% Screeni

    10/29/25 4:05:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

    Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible individuals prefer a blood test for colorectal cancer and lung cancer compared with traditional screening methods Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators will present data showing the critical role of blood-based testing in increasing cancer screening adherence at the American College of Gastroenterology (ACG) 2025 Annual Meeting in Phoenix, Arizona taking place Friday, October 24 – Wednesday, October 29, 2025. Building off findings from Guardant

    10/26/25 3:01:00 PM ET
    $GH
    Medical Specialities
    Health Care

    $ALGM
    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Allegro MicroSystems Appoints Troy Coleman as Senior Vice President, General Manager, Products

    MANCHESTER, N.H., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. ("Allegro") (NASDAQ:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy-efficient systems, today announced the appointment of Troy Coleman as Senior Vice President, General Manager, Products, effective October 14, 2025. Troy will be responsible for leading our product portfolios, driving strategic growth, innovation, and market leadership in our core power and sensing solutions. "We are thrilled to welcome Troy to Allegro," said Mike Doogue, President and Chief Executive Officer. "Troy's leadership, deep industry experience, and proven ability to grow profitable bus

    10/14/25 8:00:21 AM ET
    $ALGM
    Semiconductors
    Technology

    Alex M. Azar II Joins Guardant Health Board of Directors

    Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary of the U.S. Department of Health and Human Services (HHS), Secretary Azar had oversight and management of agencies critical to all Americans' health care including the Centers for Medicare and Medicaid Services, the Food and Drug Administration, and the Center for Disease Control and Prevention. "We're honored to welcome Secretary Azar to Guardant's board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Secretary Azar has served at the senior-most levels of government as well as th

    9/15/25 4:07:00 PM ET
    $GH
    Medical Specialities
    Health Care

    Kopin Announces Appointment of Erich Manz as Chief Financial Officer

    Kopin Corporation (NASDAQ:KOPN) a leading provider of application-specific optical systems and high-performance microdisplays for defense, training, enterprise, industrial, consumer and medical products, today announced the appointment of Erich Manz as Chief Financial Officer. Mr. Manz is an accomplished executive, bringing over three decades of financial and accounting experience in sensing, application-specific analog power and semiconductor technology markets. Mr. Manz will replace Rich Sneider, who announced his retirement in May. "We are in the midst of an exciting evolutionary journey at Kopin that can unlock the potential of application-specific optical solutions and high-perform

    8/7/25 4:15:00 PM ET
    $ALGM
    $KOPN
    Semiconductors
    Technology

    $ALGM
    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

    For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

    5/28/21 1:05:48 PM ET
    $AMGN
    $GH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical Specialities

    May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

    For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

    5/21/21 12:50:51 PM ET
    $JNJ
    $GH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities